Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.

Figen Öztürk Ergür Murat Yıldız Melahat Uzel Şener Suna Kavurgacı Ayperi Öztürk

Published in: Sao Paulo medical journal = Revista paulista de medicina (2022)

In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.

Keyphrases

coronavirus disease
sars cov
respiratory failure
respiratory syndrome coronavirus
extracorporeal membrane oxygenation